What is the price of Liminal BioSciences Inc. (LMNL)

The price of Liminal BioSciences Inc. (LMNL) is $8.50

What is the market cap of Liminal BioSciences Inc. (LMNL)

The market cap of Liminal BioSciences Inc. (LMNL) is $719.10K

Liminal BioSciences Inc. (LMNL) Revenue

Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.

Year	Revenue	Change
Not enough data for the provided dates.

Year

Revenue

Change

Not enough data for the provided dates.

Company	Revenue	Revenue Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$10.11B	-	BE

Company

Revenue

Revenue Difference

Country